# Percutek Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/percutek-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.huamaitaike.com
- Latest round: Series F (Dec 22, 2021)
- Investors on record: 19

## About

Established in 2011 and headquartered in Beijing, China, Beijing Huamai Taike Medical Devices Co., Ltd., trading under the name Percutek Therapeutics, focuses on the innovation and clinical application of medical devices for vascular disease treatment. The company has developed a portfolio of interventional devices used across multiple areas including aortic, peripheral, and neurovascular intervention. Over the years, Percutek Therapeutics has expanded its R&D and manufacturing capabilities to enhance product quality and meet clinical demand in China’s cardiovascular healthcare sector.

The company provides a range of medical devices for vascular intervention, including the PERCUTEK AAA Stent-Graft for abdominal aortic aneurysm repair, the PERCUTEK TBAD Stent-Graft for thoracic aortic dissection, the Huamai Vein Stripping Guidewire for venous intervention, as well as hydrophilic guidewires and vascular closure sets for minimally invasive vascular procedures. 

The company generates revenue through the sale of its medical devices and interventional systems to hospitals, clinics and distributors in China. Income is primarily derived from sales of stent-graft systems, guidewires and vascular closure devices.

## Funding rounds

- Series F, Dec 22, 2021 — CD Capital, DYEE Capital, V Star Capital, Haisi Chuanzong Investment Management, Insight Capital, China Galaxy Securities Co., Ltd.
- Series E, Aug 1, 2020 — Oriza Holdings, Vision Plus Capital, Huashan Ruilian Fund Management, GL Ventures
- Series D, Jun 21, 2019 — General Technology Venture Capital, Everest VC, CCB International (Shenzhen) Asset Management
- Series C, Dec 1, 2017 — V Star Capital, Hangzhou Fuzhuo Venture Capital
- Series C, Jun 1, 2017 — Lapam Capital
- Series B, Jan 12, 2017 — Lilly Asia Ventures, YuanBio Venture, Sigma Square Capital, THG Ventures
- Series A, Apr 1, 2015 — CD Capital
- Angel, Feb 1, 2014 — V Star Capital

## Investors

- V Star Capital (https://capitalatlas.ai/funds/v-star-capital) — Angel, Series C, Series F
- CD Capital — Series A, Series F
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- Sigma Square Capital (https://capitalatlas.ai/funds/sigma-square-capital) — Series B
- THG Ventures (https://capitalatlas.ai/funds/thg-ventures) — Series B
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series C
- Hangzhou Fuzhuo Venture Capital (https://capitalatlas.ai/funds/hangzhou-fuzhuo-venture-capital) — Series C
- General Technology Venture Capital (https://capitalatlas.ai/funds/general-technology-venture-capital) — Series D
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series D
- CCB International (Shenzhen) Asset Management (https://capitalatlas.ai/funds/ccb-international-shenzhen-asset-management) — Series D
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series E
- Vision Plus Capital (https://capitalatlas.ai/funds/vision-plus-capital) — Series E
- Huashan Ruilian Fund Management (https://capitalatlas.ai/funds/huashan-ruilian-fund-management) — Series E
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series E
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series F
- Haisi Chuanzong Investment Management (https://capitalatlas.ai/funds/haisi-chuanzong-investment-management) — Series F
- Insight Capital — Series F
- China Galaxy Securities Co., Ltd. — Series F